PL361230A1 - Sól sodowa prawastatyny zasadniczo wolna od laktonu prawastatyny i epi-prawastatyny oraz zawierające ją kompozycje farmaceutyczne - Google Patents

Sól sodowa prawastatyny zasadniczo wolna od laktonu prawastatyny i epi-prawastatyny oraz zawierające ją kompozycje farmaceutyczne

Info

Publication number
PL361230A1
PL361230A1 PL01361230A PL36123001A PL361230A1 PL 361230 A1 PL361230 A1 PL 361230A1 PL 01361230 A PL01361230 A PL 01361230A PL 36123001 A PL36123001 A PL 36123001A PL 361230 A1 PL361230 A1 PL 361230A1
Authority
PL
Poland
Prior art keywords
pravastatin
epi
substantially free
compositions containing
lactone
Prior art date
Application number
PL01361230A
Other languages
English (en)
Inventor
Vilmos Keri
Lajos Deak
Ilona Forgacs
Csaba Szabo
Arvai Edit Nagyne
Original Assignee
Biogal Gyogyszergyar Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL361230(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Gyogyszergyar Rt. filed Critical Biogal Gyogyszergyar Rt.
Publication of PL361230A1 publication Critical patent/PL361230A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL01361230A 2000-10-05 2001-10-05 Sól sodowa prawastatyny zasadniczo wolna od laktonu prawastatyny i epi-prawastatyny oraz zawierające ją kompozycje farmaceutyczne PL361230A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
PCT/US2001/031230 WO2002030415A1 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Publications (1)

Publication Number Publication Date
PL361230A1 true PL361230A1 (pl) 2004-10-04

Family

ID=22897222

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01361230A PL361230A1 (pl) 2000-10-05 2001-10-05 Sól sodowa prawastatyny zasadniczo wolna od laktonu prawastatyny i epi-prawastatyny oraz zawierające ją kompozycje farmaceutyczne

Country Status (18)

Country Link
EP (1) EP1330245A4 (pl)
JP (6) JP3737801B2 (pl)
KR (1) KR20030059173A (pl)
CN (1) CN1468098A (pl)
AU (1) AU2002211462A1 (pl)
CA (1) CA2422744A1 (pl)
CZ (1) CZ20031166A3 (pl)
HR (1) HRP20030347A2 (pl)
HU (1) HUP0400913A2 (pl)
IL (1) IL155194A0 (pl)
IS (1) IS6766A (pl)
MX (1) MXPA03002963A (pl)
NO (1) NO20031532L (pl)
NZ (1) NZ525631A (pl)
PL (1) PL361230A1 (pl)
SK (1) SK5232003A3 (pl)
WO (1) WO2002030415A1 (pl)
ZA (1) ZA200302313B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481674B1 (en) * 1999-11-30 2008-01-02 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
WO2001039768A1 (en) * 1999-11-30 2001-06-07 Biogal Gyogyszergyar Rt Process for recovering statin compounds from a fermentation broth
HK1049441A1 (zh) 1999-12-14 2003-05-16 Biogal Gyogyszergyar Rt 普伐他丁钠的崭新形式
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
PL1641447T3 (pl) * 2003-11-24 2009-04-30 Teva Gyogyszergyar Zartkoerueen Muekoedoe Reszvenytarsasag Sposób oczyszczania prawastatyny
KR20070038553A (ko) 2004-08-06 2007-04-10 트렌스폼 파마수티컬스 인코퍼레이티드 신규한 스타틴 약제학적 조성물 및 관련된 치료방법
ES2254028B1 (es) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de pravastatina sodica purificada.
WO2006091980A1 (en) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Process of purifying tadalafil
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN114031496B (zh) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (pl) * 1973-09-29 1977-06-11
IE43790B1 (en) * 1975-02-07 1981-06-03 Glaxo Lab Ltd -lactam antibiotic in purified form
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd 3−ヒドロキシ−ml−236b誘導体の製造法
JPS5890509A (ja) * 1981-11-25 1983-05-30 Sankyo Co Ltd 高コレステロ−ル血症治療用組成物
JPH01190661A (ja) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk 4,4′−ジヒドロキシジフエニルスルホンの精製法
JP2739328B2 (ja) * 1988-09-14 1998-04-15 日本ケミファ株式会社 ベンズイミダゾール化合物の精製方法
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (ja) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd 光学活性α−カルバモイルアルカン酸誘導体およびその製法
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
EP0754239B1 (en) * 1994-03-31 1997-10-08 Cultor Ltd. Process for natamycin recovery
WO1997006128A1 (en) * 1995-08-03 1997-02-20 Gist-Brocades B.V. Selective process for the deacylation of acylated compounds
JPH09124655A (ja) * 1995-11-01 1997-05-13 Sankyo Co Ltd 新規スクアレンシンターゼ阻害活性化合物
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
JP2000229855A (ja) * 1998-12-07 2000-08-22 Satoshi Takebe プラバスタチンナトリウム錠
SK10932001A3 (sk) * 1999-02-03 2002-06-04 Institute For Drug Research Ltd. Mikrobiálny spôsob výroby pravastatínu
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
WO2001039768A1 (en) * 1999-11-30 2001-06-07 Biogal Gyogyszergyar Rt Process for recovering statin compounds from a fermentation broth
HRP20030347A2 (en) * 2000-10-05 2005-04-30 Teva Gy�gyszergy�r R�szv�nyt�rsas�g Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Also Published As

Publication number Publication date
JP2004510817A (ja) 2004-04-08
SK5232003A3 (en) 2004-06-08
HUP0400913A2 (en) 2006-11-28
WO2002030415A9 (en) 2002-10-31
JP2006036781A (ja) 2006-02-09
EP1330245A1 (en) 2003-07-30
HRP20030347A2 (en) 2005-04-30
JP3737801B2 (ja) 2006-01-25
ZA200302313B (en) 2004-03-25
KR20030059173A (ko) 2003-07-07
EP1330245A4 (en) 2004-10-20
MXPA03002963A (es) 2005-01-25
JP2005013238A (ja) 2005-01-20
JP2015212300A (ja) 2015-11-26
CZ20031166A3 (cs) 2004-04-14
AU2002211462A1 (en) 2002-04-22
CN1468098A (zh) 2004-01-14
CA2422744A1 (en) 2002-04-18
IS6766A (is) 2003-04-01
NO20031532D0 (no) 2003-04-04
IL155194A0 (en) 2003-11-23
NZ525631A (en) 2005-05-27
JP2009268479A (ja) 2009-11-19
NO20031532L (no) 2003-04-04
WO2002030415A1 (en) 2002-04-18
JP2013128486A (ja) 2013-07-04

Similar Documents

Publication Publication Date Title
HRP20030347A2 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU3459702A (en) Branched primary alcohol compositions and derivatives thereof
HUP0400691A3 (en) Pyrimidineamines as angiogenesis modulators and pharmaceutical compositions containing them
HUP0302297A3 (en) Substituted thioacetamides and pharmaceutical compositions containing them
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
ZA200106648B (en) Synthesis of low silocon sodium X zeolite.
IL137363A0 (en) Pharmaceutical compositions containing mupirocin
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
GB0118579D0 (en) Pharmaceutical composition containing citalopram
IL154068A0 (en) Highly purified simvastatin compositions
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
IL150187A0 (en) Novel forms of pravastatin sodium
GB0029847D0 (en) Preparation of spheroids
AU4834101A (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
AU9482601A (en) Tocol-based compositions containing amiodarone
IL159614A0 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
HUP0302531A3 (en) Pharmaceutical compositions containing citalopram
HK1055685A (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU2001272490A1 (en) Use of galiella lactone
AU2001264324A1 (en) Method of stabilizing medicinal compositions containing pravastatin
AU2001294374A1 (en) 2-acylindenes and these containing perfume compositions
AU7057701A (en) New use as antihelmintics of albofungin and analogs
GB0018502D0 (en) New compositions of matter
ZA200204500B (en) Forms of pravastatin sodium.
AU2002216388A1 (en) Benzofuran derivatives and pharmaceutical compositions containing the same